Core Insights - Silo Pharma, Inc. announced promising results from sterilization and dissolution tests of its SP-26 ketamine-loaded implant for fibromyalgia and chronic pain, indicating stability and consistent drug release [1][2] - The SP-26 implant demonstrated over 80% drug release over a 7-day period, highlighting its effective time-release formulation [2] - The company is also developing SPC-15, a novel serotonin 4 receptor agonist for PTSD and anxiety, which may qualify for the FDA's streamlined 505(b)(2) regulatory pathway [3] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on novel therapeutics for underserved conditions, including chronic pain and stress-induced psychiatric disorders [3] - The company's lead programs include SP-26 for chronic pain relief and SPC-15 for PTSD, with additional preclinical programs targeting Alzheimer's disease and multiple sclerosis [3]

Core Viewpoint - Silo Pharma, Inc. has announced a partnership with Sever Pharma Solutions to scale up the production of its SP-26 ketamine-based injectable implant aimed at treating chronic pain and fibromyalgia, with ongoing analytical testing to optimize the formulation [1][2]. Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on creating novel therapeutics for underserved conditions, including chronic pain and psychiatric disorders [4]. - The company's lead program, SPC-15, targets PTSD and stress-induced anxiety, while SP-26 is designed as a time-release ketamine implant for chronic pain relief [4]. Product Details - SP-26 is a ketamine-based injectable dissolvable polymer implant that aims to safely regulate dosage and time release for pain relief [3]. - The implant is currently undergoing pre-clinical studies to finalize its dosage and formulation, with the potential to qualify for the FDA's streamlined 505(b)(2) regulatory pathway if clinically successful [2]. Collaboration and Development - The collaboration with Sever Pharma Solutions builds on previous successful production and validation of the ketamine implants, indicating a strong partnership in advancing the product [2]. - The ongoing analytical testing will help in selecting the optimal final dosage and formulation for animal studies [2].

Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an agreement with WuXi AppTec (Hong Kong) Limited, a leading global contract research organization (CRO) ...

The gross proceeds to the Company from the offering were approximately $2.1 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The unregistered warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with ...

SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per share in a registered direct offering priced at-the-market under Nasdaq rule ...

SARASOTA, FL, July 16, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer's drug SPC-14. Silo intends to utilize the FDA's streamlined 505(b)(2) pathway for SPC-14 ...

Extensive Issued and Pending IP Patent Applications Acquired with License Agreement "In our opinion, the execution of the exclusive license agreement for our SPC-15 product is a critical step for our Company which we believe could increase shareholder value in the future, subject to FDA approval if and when received," said Silo CEO Eric Weisblum. About Silo Pharma This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation R ...

Core Insights - Silo Pharma is advancing its lead asset, SPC-15, towards first-in-human trials for PTSD, with a significant milestone being the completion of a large animal GLP study [2][10][11] - The company has partnered with AmplifyBio since 2022 to facilitate the development of SPC-15 through pre-clinical studies [2][6] - SPC-15 is an intranasal formulation that acts as a serotonin 4 receptor agonist, targeting PTSD and other stress-induced disorders [8][12] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on novel therapeutics for underserved conditions, including stress-induced psychiatric disorders and chronic pain [12] - The company is developing both traditional therapies and psychedelic treatments, with SPC-15 being its lead program [12] - Other programs include SP-26, a ketamine-loaded implant for fibromyalgia, and SPC-14, an intranasal compound for Alzheimer's disease [12] Research and Development - The upcoming GLP study will involve a 28-day repeat intranasal dosing regimen with a 14-day recovery period [7] - Previous studies have shown that SPC-15 has rapid absorption and good exposure over a 24-hour period, indicating a potential once-per-day dosing regimen for humans [7][8] - The company has submitted a pre-IND briefing package to the FDA, marking a step towards seeking IND approval for clinical trials [11]

Analytical testing has confirmed optimal formulation for upcoming studies SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a successful series of development activities for the Company's SP-26 ketamine implant therapeutic targeting fibromyalgia and chronic pain. An ...

SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a successful series of development activities for the Company's SP-26 ketamine implant therapeutic targeting fibromyalgia and chronic pain. An ongoing pre-clinical research study of SP-26 is underway involving analyt ...